Ibio Inc. has expanded its artificial intelligence (AI)-powered technology offering with the launch of Shieldtx, an antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue.

Virpax Pharmaceuticals Inc. expects to submit an IND application for Envelta (MET-LENK) around the middle of next year following review of comments made by the FDA on the company’s pre-IND submission. If successful, first-in-human trials would also be expected to begin around the middle of the year.

Researchers from Medigene AG recently presented the discovery and preclinical evaluation of first-in-class, third-generation T-cell receptor T-cell (TCR-T) therapies, MDG-1015 and MDG-2011.

In work conducted at China Pharmaceutical University, synthesis and optimization of a new series of cyclin-dependent kinase 9 (CDK9) inhibitors bearing a flavonoid scaffold led to the identification of compound [I] as the lead candidate, with IC50 of 6.7 nM for CDK9 and >80-fold selectivity over CDK2 and most other CDK family members.

Antibiotic resistance represents a global threat that leads to high morbidity and mortality. There is an urgent need for new strategies to combat persistent and resistant bacteria.

Researchers led by faculty at the Ohio State University College of Medicine have identified a previously unrecognized connection between microtubule-associated protein 6 (MAP6) and the Kv3.1 voltage-gated potassium (K+) channel – two proteins with different functions. The physical interaction between two neuronal proteins appears to maintain normal movement, anxiety and long-term recognition memory in mice.